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Type 1 diabetes is an autoimmune disease characterized by inflammation of pancreatic islets and destruction
of β cells by the immune system. Opioids have been shown to modulate a number of immune functions,
including T helper 1 (Th1) and T helper 2 (Th2) cytokines. The immunosuppressive effect of long-term
administration of opioids has been demonstrated both in animal models and humans. The aim of this study
was to determine the effect of methadone, a μ-opioid receptor agonist, on type 1 diabetes. Administration of
multiple low doses of streptozotocin (STZ) (MLDS) (40mg/kg intraperitoneally for 5 consecutive days) to mice
resulted in autoimmune diabetes. Mice were treated with methadone (10mg/kg/day subcutaneously) for
24days. Blood glucose, insulin and pancreatic cytokine levels were measured. Chronic methadone treatment
significantly reduced hyperglycemia and incidence of diabetes, and restored pancreatic insulin secretion in
the MLDS model. The protective effect of methadone can be overcome by pretreatment with naltrexone, an
opioid receptor antagonist. Also, methadone treatment decreased the proinflammatory Th1 cytokines
[interleukin (IL)-1β, tumor necrosis factor-α and interferon-γ] and increased anti-inflammatory Th2
cytokines (IL-4 and IL-10). Histopathological observations indicated that STZ-mediated destruction of β cells
was attenuated by methadone treatment. It seems that methadone as an opioid agonist may have a
protective effect against destruction of β cells and insulitis in the MLDS model of type 1 diabetes.
© 2008 Elsevier Inc. All rights reserved.
Introduction
Insulin-dependent diabetes mellitus (IDDM) is an autoimmune
disease. Type 1 diabetes results from specific destruction of the
insulin-producing β-cells in the pancreatic islets of Langerhans by the
immune system (Bach, 1994). It is believed that destruction of
pancreatic islet β cells and consequent IDDM is the result of perturbed
immune regulation. Multiple environmental and genetic factors make
the immune cells, particularly T lymphocytes to invade islet β cells
and cause pancreatic inflammation (Rabinovitch and Suarez-Pinzon,
1998). This inflammatory response is known as insulitis (Pukel et al.,
1988). Cytotoxicity of T cells towards islet β cells is generated by
cytokines and free radicals. Autoreactive T helper 1 (Th1) cells and
proinflammatory cytokines [interferon (IFN)-γ, interleukin (IL)-1 and
tumor necrosis factor (TNF)-α] are pathogenic to islet β cells, whereas
T helper 2 (Th2) cells and their cytokines (IL-4 and IL-10) are
protective against destruction of β cells (Rabinovitch, 1998). Blocking
the function of type 1 cytokines and increasing type 2 cytokines can
reduce the development of IDDM in rodent models (Rabinovitch and
Suarez-Pinzon, 1998).
Multiple lowdoses of streptozotocin (STZ) (MLDS) canbe used as an
animal model for type 1 diabetes. STZ is a potent alkylating agent and
damages islet β cells selectively by two different mechanisms. First,
when given in a single high dose, it rapidly destroys islet β cells by
direct cytotoxic action, most probably due to DNA alkylation. Second,
when STZ is given inmultiple lowdoses, it induces inflammation of the
islets by immune cells, with subsequent destruction of β cells and
progressive hyperglycemia within a few days. This model of diabetes
shares many histological and clinical features with human type 1
diabetes and requires the participation of macrophages and T cells
(Like and Rossini, 1976; Rossini et al., 1978; Papaccio et al., 2000).
Therefore, the MLDS model has been applied extensively to study the
immune pathways (e.g. cytokine signaling, Fas ligand transduction and
cytokine-induced β cell apoptosis) involved in destruction of islet β
cells (Kawasaki et al., 2004; Rees and Alcolado, 2005).
It is believed that the endogenous opioid system regulates immune
functions. Previous studies have established the presence of opioid
receptors (μ, κ and δ) on cells of the immune system (Mehrishi and
Mills, 1983). Many animal and human studies have shown that opioids
induce immunosuppressive effects, and chronic opioid use has been
associated with an increased incidence of infection (Budd, 2006).
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